Immunotherapy combination for rectal cancer with liver or lung spread
Part of Cancer, Digestive system, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests a combination therapy that includes an immunotherapy drug (called anti-PD-1) for people with rectal cancer that has spread to the liver or lungs. The goal is to see if this treatment can help shrink or control the cancer, and it may be an option if you haven't had treatment yet.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 75 years old
- Have rectal cancer that has spread to your liver or lungs (but not other organs)
- Not have received treatment for this cancer before
- Have a specific type of rectal cancer called 'adenocarcinoma' that is located less than 10 cm from the anus
- Have good overall health (as measured by a performance score) and adequate organ function
- Have a stable type of cancer (called MSS) with known genetic markers
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding an immunotherapy drug called tislelizumab to standard chemotherapy and radiation can help patients with early-stage rectal cancer (cancer within 3 cm of the opening of the rectum) avoid surgery or improve surgery outcomes. The goal is to see if this combination is safe and effective.
This trial tests a new combination of chemotherapy, radiation, and an immunotherapy drug called tislelizumab before surgery for rectal cancer that has grown locally. The goal is to see if this approach can shrink the tumor more effectively and improve surgical outcomes.
This trial tests a combination of immunotherapy drugs (PD-1 antibody and IL-2) with chemotherapy (CapeOX) in people with very low rectal cancer that hasn't spread. The goal is to preserve the rectum by shrinking the tumor, avoiding surgery, and increasing the chance of a complete response.
This trial is testing whether adding the immunotherapy drug tislelizumab to standard total neoadjuvant treatment (chemotherapy and radiation before surgery) can improve outcomes for people with locally advanced rectal cancer. The goal is to see if the combination helps shrink the tumor more than standard treatment alone.
This trial tests a combination of immunotherapy (tislelizumab) and standard chemotherapy and radiation before surgery for low rectal cancer. The goal is to help shrink or eliminate the tumor so surgery might be less invasive or not needed, allowing you to keep your rectum.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
Hear when a new Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.